WOR.AU

12.95

-0.31%↓

WOR.AU

12.95

-0.31%↓

WOR.AU

12.95

-0.31%↓

WOR.AU

12.95

-0.31%↓

WOR.AU

12.95

-0.31%↓

Search

CSL Ltd

Fechado

SetorSetor Industrial

269.6 -0.89

Visão Geral

Variação de preço das ações

24h

Atual

Mín

269.6

Máximo

269.6

Indicadores-chave

By Trading Economics

Rendimento

2B

Vendas

-5.7B

2.5B

P/E

Médio do Setor

31.616

37.329

EPS

4.13

Rendimento de Dividendos

1.04

Margem de lucro

24.437

Funcionários

32,698

EBITDA

-2.4B

858M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+12.93% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.04%

2.32%

Próximos Ganhos

19 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.6B

128B

Abertura anterior

270.49

Fecho anterior

269.6

Sentimento de Notícias

By Acuity

50%

50%

198 / 460 Ranking em Industrials

CSL Ltd Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de abr. de 2025, 09:39 UTC

Grandes Movimentos do Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10 de fev. de 2025, 21:55 UTC

Ganhos

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 de fev. de 2025, 21:34 UTC

Ganhos

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

17 de jun. de 2025, 02:15 UTC

Conversa de Mercado

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9 de abr. de 2025, 07:01 UTC

Conversa de Mercado

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21 de mar. de 2025, 02:03 UTC

Conversa de Mercado

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 de fev. de 2025, 22:30 UTC

Conversa de Mercado

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 de fev. de 2025, 21:40 UTC

Ganhos

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 de fev. de 2025, 21:19 UTC

Ganhos

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 de fev. de 2025, 21:13 UTC

Ganhos

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 de fev. de 2025, 21:12 UTC

Ganhos

CSL Interim Dividend US$1.30/Security

10 de fev. de 2025, 21:12 UTC

Ganhos

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 de fev. de 2025, 21:11 UTC

Ganhos

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 de nov. de 2024, 03:53 UTC

Conversa de Mercado

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 de out. de 2024, 22:53 UTC

Conversa de Mercado

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 de out. de 2024, 22:20 UTC

Conversa de Mercado

CSL Bull Looking for Update on Gross Margin -- Market Talk

Comparação entre Pares

Variação de preço

CSL Ltd Previsão

Preço-alvo

By TipRanks

12.93% parte superior

Previsão para 12 meses

Média 305.324 AUD  12.93%

Máximo 330 AUD

Mínimo 275 AUD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para CSL Ltd - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

11 ratings

9

Comprar

2

Manter

0

Vender

Sentimento

By Acuity

198 / 460 Ranking em Setor Industrial

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.